<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03146910</url>
  </required_header>
  <id_info>
    <org_study_id>SASL39 - Swiss PBC Cohort</org_study_id>
    <nct_id>NCT03146910</nct_id>
  </id_info>
  <brief_title>Swiss Primary Biliary Cholangitis Cohort Study</brief_title>
  <official_title>Swiss Primary Biliary Cholangitis Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Epatocentro Ticino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Epatocentro Ticino</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research project in which biological material is sampled and health-related medical data is
      collected. In addition, already existing health-related medical data are used for further
      research. Coded data are used.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolment visit and one follow-up visit at least once a year are planned.

      Whole blood is collected for biobanking once a year. Optionally, if available and collected
      during normal clinical procedures, liver fragments are obtained.

      To collect high quality prospective data on a rare disease in order to elucidate
      epidemiology, natural history, response to treatment and outcome. In addition, the biobank
      allows addressing specific scientific issues on a variety of open questions. The cohort will
      provide a platform for carrying out scientific research projects on PBC. In addition, the
      cohort will allow collaboration with reference networks on PBC abroad.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Disease course</measure>
    <time_frame>3 years</time_frame>
    <description>Observing disease course</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease features</measure>
    <time_frame>3 years</time_frame>
    <description>Observing disease features in Swiss population and see if they are similar to other countries'</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response to treatment</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Transplantation-free survival rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Liver Cirrhosis, Biliary</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with Primary biliary cholangitis according to recognized criteria
        (European Association for the Study of the Liver. EASL Clinical Practice Guidelines:
        management of cholestatic liver diseases). Subjects with isolated anti-mitochondrial
        antibodies and/or isolated PBC-specific anti-nuclear antibodies are also included.
        Patients/subjects aged at least 18 years and living in Switzerland are included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnose of Primary biliary cholangitis (according to EASL Clinical Practice
             Guidelines: management of cholestatic liver diseases).

          -  Subjects with isolated anti-mitochondrial antibodies and/or isolated PBC-specific
             anti-nuclear antibodies are also included

          -  Patients/subjects aged at least 18 years and living in Switzerland are included

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Benedetta Terziroli Beretta-Piccoli, MD</last_name>
    <phone>+41919608503</phone>
    <email>benedetta.terziroli@hin.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione Epatocentro Ticino</name>
      <address>
        <city>Lugano</city>
        <state>Ticino</state>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benedetta Terziroli Beretta-Piccoli, MD</last_name>
      <phone>+41919608507</phone>
      <email>benedetta.terziroli@hin.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guido Stirnimann, MD</last_name>
      <phone>+4131 632 09 00</phone>
      <email>stefania.casu@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève, Service de Gastroentérologie &amp; Hépatologie, Département des Spécialités</name>
      <address>
        <city>Geneve</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Goossens, MD</last_name>
      <phone>+4122 372 93 55</phone>
      <email>Nicolas.Goossens@hcuge.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baselland</name>
      <address>
        <city>Liestal</city>
        <zip>4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena Filipowicz-Sinnreich, MD</last_name>
      <phone>+41 61 925 23 60</phone>
      <email>Magdalena.Filipowicz@ksbl.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St.Gallen</name>
      <address>
        <city>Sankt Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Semela, MD</last_name>
      <phone>+4171 4941216</phone>
      <email>David.Semela@kssg.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Mertens, MD</last_name>
      <phone>+41 44 255 11 11</phone>
      <email>Joachim.mertens@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2017</study_first_submitted>
  <study_first_submitted_qc>May 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2017</study_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

